VIVO Meridian Bioscience, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

VIVO [NASD]

Meridian Bioscience, Inc.

Healthcare | Diagnostics & Research | USA

statements

Index	-	P/E	50.10	EPS (ttm)	0.50	Insider Own	0.90%	Shs Outstand	42.83M	Perf Week	9.43%
Market Cap	1.02B	Forward P/E	24.58	EPS next Y	1.02	Insider Trans	16.22%	Shs Float	42.31M	Perf Month	54.78%
Income	21.40M	PEG	2.95	EPS next Q	0.25	Inst Own	85.30%	Short Float	7.14%	Perf Quarter	184.17%
Sales	204.00M	P/S	5.02	EPS this Y	10.10%	Inst Trans	-2.87%	Short Ratio	3.29	Perf Half Y	154.46%
Book/sh	4.78	P/B	5.22	EPS next Y	32.68%	ROA	6.50%	Target Price	19.00	Perf Year	113.61%
Cash/sh	1.21	P/C	20.65	EPS next 5Y	17.00%	ROE	10.90%	52W Range	5.51 - 24.94	Perf YTD	155.37%
Dividend	-	P/FCF	37.52	EPS past 5Y	-7.30%	ROI	9.60%	52W High	0.04%	Beta	0.93
Dividend %	-	Quick Ratio	2.50	Sales past 5Y	1.30%	Gross Margin	58.50%	52W Low	352.81%	ATR	1.18
Employees	660	Current Ratio	3.60	Sales Q/Q	14.10%	Oper. Margin	14.40%	RSI (14)	73.87	Volatility	5.24% 6.01%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	31.90%	Profit Margin	10.50%	Rel Volume	0.70	Prev Close	24.48
Shortable	Yes	LT Debt/Eq	0.24	Earnings	May 08 BMO	Payout	0.00%	Avg Volume	918.70K	Price	24.95
Recom	1.00	SMA20	22.65%	SMA50	46.04%	SMA200	125.44%	Volume	640,415	Change	1.92%

May-11-20

Upgrade

William Blair

Mkt Perform → Outperform

May-01-19

Upgrade

Piper Jaffray

Underweight → Neutral

$15 → $11

Apr-03-19

Downgrade

Canaccord Genuity

Hold → Sell

$17 → $11

Jan-26-18

Reiterated

Canaccord Genuity

Hold

$14 → $16

Mar-28-17

Initiated

CL King

Neutral

Mar-28-16

Reiterated

Canaccord Genuity

Hold

$18 → $19

Sep-10-15

Reiterated

Canaccord Genuity

Hold

$19 → $18

Jul-27-15

Reiterated

Canaccord Genuity

Hold

$20 → $19

May-04-15

Reiterated

Canaccord Genuity

Hold

$19 → $20

Nov-06-14

Downgrade

Robert W. Baird

Outperform → Neutral

$22 → $22

Jul-27-12

Downgrade

Canaccord Genuity

Buy → Hold

Apr-25-11

Upgrade

Wedbush

Underperform → Neutral

$18 → $22

Mar-24-11

Upgrade

Canaccord Genuity

Hold → Buy

$30

Nov-16-10

Initiated

Canaccord Genuity

Hold

$21

Apr-07-10

Initiated

Wedbush

Underperform

$18

Nov-13-09

Reiterated

Caris & Company

Average

$21 → $20

Jul-07-09

Initiated

Caris & Company

Average

$21

Mar-06-09

Initiated

William Blair

Mkt Perform

Oct-14-08

Initiated

Lazard Capital

Buy

$30

Jul-21-08

Upgrade

Hilliard Lyons

Neutral → Long-term Buy

Jul-01-20 09:37AM	The Zacks Analyst Blog Highlights: Galiano Gold, Fortinet, Meridian Bioscience, Crescent Capital BDC and NextEra Energy Zacks
Jun-30-20 09:56AM	Zacks.com featured highlights include: eXp World, Lakeland Industries, Meridian Bioscience, Kiniksa Pharmaceuticals and iClick Interactive Asia Group Zacks +6.93%
Jun-29-20 08:09AM	5 Stocks With Recent Price Strength Amid Spike in Coronavirus Zacks
Jun-24-20 11:18AM	New Strong Buy Stocks for June 24th Zacks
Jun-22-20 11:59AM	Hedge Funds Have Never Been This Bullish On Meridian Bioscience, Inc. (VIVO) Insider Monkey
Jun-18-20 09:15AM	Meridian Bioscience (VIVO) Soars to 52-Week High, Time to Cash Out? Zacks
Jun-15-20 03:51PM	Edited Transcript of VIVO.OQ earnings conference call or presentation 8-May-20 2:00pm GMT Thomson Reuters StreetEvents
May-29-20 08:00AM	Meridian Bioscience to Participate in the 40th Annual William Blair Growth Stock Conference GlobeNewswire +9.03%
May-26-20 08:00AM	Meridian Bioscience Announces It Will Supply Reagents for the Manufacturing of Tens of Millions of COVID-19 Antibody Tests Per Month GlobeNewswire
May-20-20 04:20PM	Meridian Bioscience Promotes Tony Serafini-Lamanna to Executive Vice President of Diagnostics GlobeNewswire
May-12-20 04:20PM	Top Stock Picks for Week of May 11, 2020 Zacks
May-09-20 08:01PM	Meridian Bioscience Inc (VIVO) Q2 2020 Earnings Call Transcript Motley Fool
May-08-20 08:55AM	Meridian Bioscience (VIVO) Q2 Earnings and Revenues Surpass Estimates Zacks +6.97%
08:02AM	Recap: Meridian Bioscience Q2 Earnings Benzinga
07:30AM	Meridian Bioscience Reports Second Quarter 2020 Operating Results; Raises Guidance on Strength of COVID-19 Related Products GlobeNewswire
May-06-20 05:51PM	Why Meridian Bioscience Stock Shot Up Nearly 13% Today Motley Fool +12.83%
08:00AM	Meridian Bioscience Partners with QuantuMDx on COVID-19 Assay GlobeNewswire
May-01-20 12:30PM	Analysts Estimate Meridian Bioscience (VIVO) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-30-20 10:51AM	Meridian Bioscience Announces Closing of Transaction to Acquire Exalenz Bioscience GlobeNewswire
Apr-27-20 11:56AM	Meridian Bioscience Simplifies COVID-19 Sample Prep and Eliminates Dependence on Reagents in Short Supply GlobeNewswire +7.21%
Apr-16-20 09:00AM	Meridian Bioscience To Hold Second Quarter 2020 Financial Results Conference Call On May 8, 2020 GlobeNewswire +5.39%
Apr-15-20 12:23PM	How Should Investors Feel About Meridian Bioscience, Inc.'s (NASDAQ:VIVO) CEO Pay? Simply Wall St.
Apr-14-20 09:34AM	Meridian Bioscience offers SARS-CoV-2 antigens for COVID-19 Antibody Tests GlobeNewswire +11.70%
Apr-02-20 10:11AM	Cincinnati firms stock jumps along with sales because of coronavirus American City Business Journals +10.33%
07:30AM	MERIDIAN BIOSCIENCE ANNOUNCES BETTER-THAN-EXPECTED PRELIMINARY SECOND QUARTER FISCAL 2020 REVENUE RESULTS WITH DOUBLE-DIGIT GROWTH GlobeNewswire
Mar-16-20 11:51AM	Meridian Bioscience Supports Diagnostic Companies in Fighting Coronavirus Pandemic by Providing Zero Cost Proprietary Technology for Evaluation GlobeNewswire
08:00AM	Meridian Bioscience Announces FDA-Clearance for New Curian Analyzer and the Curian HpSA® Assay GlobeNewswire
07:15AM	Trade Alert: The President Of Meridian Bioscience, Inc. (NASDAQ:VIVO), John Kenny, Has Just Spent US$174k Buying Shares Simply Wall St.
Mar-13-20 03:27PM	How Does Meridian Bioscience's (NASDAQ:VIVO) P/E Compare To Its Industry, After The Share Price Drop? Simply Wall St. +13.64%
Mar-04-20 04:56PM	Here's how Cincinnati stocks did on Dow's 1,200-point surge American City Business Journals +7.00%
Feb-26-20 02:24PM	How Does Meridian Bioscience's (NASDAQ:VIVO) P/E Compare To Its Industry, After The Share Price Drop? Simply Wall St.
08:00AM	Meridians Novel Air-Dryable qPCR Mix Decreases Costs and Simplifies Workflows for Molecular Test Manufacturers GlobeNewswire
Feb-24-20 12:18PM	UPDATE: These Cincinnati stocks took biggest hits in Monday's selloff American City Business Journals
Feb-20-20 10:25AM	Meridian Bioscience, Inc. (NASDAQ:VIVO) Earns Among The Best Returns In Its Industry Simply Wall St.
Feb-19-20 01:16PM	One of Cincinnatis largest public companies to acquire rival for $49M American City Business Journals
09:15AM	Meridian Bioscience Signs Definitive Agreement to Acquire Exalenz Bioscience; Adds State-Of-The-Art Urea Breath Test Diagnostics Platform GlobeNewswire
Feb-11-20 08:01AM	Edited Transcript of VIVO earnings conference call or presentation 7-Feb-20 3:00pm GMT Thomson Reuters StreetEvents
Feb-07-20 08:45AM	Meridian Bioscience (VIVO) Beats Q1 Earnings Estimates Zacks -7.03%
07:30AM	Meridian Bioscience Reports First Quarter Fiscal 2020 Operating Results and Reaffirms 2020 Guidance GlobeNewswire
Jan-31-20 12:30PM	Analysts Estimate Meridian Bioscience (VIVO) to Report a Decline in Earnings: What to Look Out for Zacks
Jan-28-20 02:23PM	Coronavirus update: Vaccine stocks retreat and airport screening expands to 20 U.S. airports MarketWatch -10.52%
Jan-27-20 01:19PM	Stock soars for Cincinnati firm that could help combat coronavirus American City Business Journals +20.67%
09:17AM	Meridian Bioscience Lyo-Ready 1-Step RT-qPCR Mix is Used in the Development of Molecular Diagnostics for New Coronavirus Outbreak GlobeNewswire
Jan-23-20 08:00AM	Meridian Launched a New High-Fidelity Polymerase to Offer Robust Amplification for NGS and PCR Applications GlobeNewswire
Jan-21-20 10:11AM	Do You Like Meridian Bioscience, Inc. (NASDAQ:VIVO) At This P/E Ratio? Simply Wall St.
Jan-15-20 04:30PM	Meridian Bioscience to Hold First Quarter 2020 Financial Results Conference Call on February 7, 2020 GlobeNewswire
Dec-30-19 12:48PM	A Duo of Underperforming Stocks to Ease GuruFocus.com
Dec-20-19 02:40PM	Is There An Opportunity With Meridian Bioscience, Inc.'s (NASDAQ:VIVO) 22% Undervaluation? Simply Wall St.
Dec-11-19 09:49AM	Meridian Bioscience, Inc. (VIVO): Are Hedge Funds Right About This Stock? Insider Monkey
Nov-15-19 02:39PM	Multimillion-dollar settlement proposed in lawsuit over stock price at one of regions largest public companies American City Business Journals
Nov-14-19 01:08PM	Edited Transcript of VIVO earnings conference call or presentation 7-Nov-19 3:00pm GMT Thomson Reuters StreetEvents
Nov-07-19 09:15AM	Meridian Bioscience (VIVO) Q4 Earnings and Revenues Surpass Estimates Zacks -16.24%
07:30AM	Meridian Bioscience Reports Fourth Quarter and Full-Year Fiscal 2019 Operating Results and Provides Fiscal 2020 Guidance GlobeNewswire
Nov-06-19 07:30AM	Meridian submits Curian analyzer and the Curian HpSA assay to the FDA GlobeNewswire
Oct-31-19 03:50PM	Is Meridian Bioscience (NASDAQ:VIVO) A Risky Investment? Simply Wall St.
10:34AM	Analysts Estimate Meridian Bioscience (VIVO) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-30-19 05:21PM	Is Meridian Bioscience, Inc. (VIVO) Going to Burn These Hedge Funds? Insider Monkey
Oct-16-19 11:00AM	Meridian Bioscience to Hold Fourth Quarter and Full Year 2019 Financial Results Conference Call on November 7, 2019 GlobeNewswire
Oct-04-19 01:13PM	How Many Meridian Bioscience, Inc. (NASDAQ:VIVO) Shares Have Insiders Sold, In The Last Year? Simply Wall St.
Aug-28-19 07:07AM	Boasting A 14% Return On Equity, Is Meridian Bioscience, Inc. (NASDAQ:VIVO) A Top Quality Stock? Simply Wall St.
Aug-23-19 09:30AM	Should Value Investors Pick Meridian Bioscience (VIVO) Now? Zacks
Aug-10-19 08:34AM	Edited Transcript of VIVO earnings conference call or presentation 30-Jul-19 2:00pm GMT Thomson Reuters StreetEvents
Jul-30-19 02:23PM	Meridian Bioscience Inc (VIVO) Q3 2019 Earnings Call Transcript Motley Fool
08:55AM	Meridian Bioscience (VIVO) Beats Q3 Earnings Estimates Zacks
07:30AM	Meridian Bioscience Reports Third Quarter 2019 Operating Results GlobeNewswire
Jul-23-19 10:32AM	Analysts Estimate Meridian Bioscience (VIVO) to Report a Decline in Earnings: What to Look Out for Zacks
Jul-10-19 04:30PM	Meridian Bioscience to Hold Third Quarter 2019 Financial Results Conference Call on July 30, 2019 GlobeNewswire
Jul-02-19 07:25AM	InMed Pharmaceuticals Appoints Catherine Sazdanoff to Board of Directors CNW Group
Jun-26-19 09:30PM	Heres What Hedge Funds Think About Meridian Bioscience, Inc. (VIVO) Insider Monkey
Jun-04-19 10:34AM	One of Cincinnatis largest public companys closes on $50M acquisition American City Business Journals
Jun-03-19 04:28PM	Meridian Bioscience Announces Closing of Transaction to Acquire Business of GenePOC GlobeNewswire
May-20-19 01:42PM	Meridian Bioscience, Inc. (NASDAQ:VIVO) Earns Among The Best Returns In Its Industry Simply Wall St.
May-09-19 08:45PM	Heres What Hedge Funds Think About Meridian Bioscience, Inc. (VIVO) Insider Monkey
May-03-19 02:21AM	Edited Transcript of VIVO earnings conference call or presentation 30-Apr-19 2:00pm GMT Thomson Reuters StreetEvents
Apr-30-19 11:50AM	Cincinnati public company could pay $120M for Canadian firm American City Business Journals -14.42%
10:38AM	Meridian Bioscience Reports Second Quarter 2019 Operating Results, Suspends Quarterly Cash Dividend, and Provides Fiscal 2019 Guidance for Pending Acquisition Business Wire
10:15AM	Meridian Bioscience (VIVO) Q2 Earnings and Revenues Top Estimates Zacks
10:10AM	Meridian Bioscience Announces Agreement to Acquire Business of GenePOC; Adds State-of-the-Art Molecular Diagnostics Platform Business Wire
09:42AM	Meridian Bioscience Reports Second Quarter 2019 Operating Results, Suspends Quarterly Cash Dividend, and Provides Fiscal 2019 Guidance for Pending Acquisition GlobeNewswire
09:41AM	Meridian Bioscience Announces Agreement to Acquire Business of GenePOC; Adds State-of-the-Art Molecular Diagnostics Platform GlobeNewswire
09:08AM	Meridian Bioscience: Fiscal 2Q Earnings Snapshot Associated Press
Apr-23-19 10:32AM	Analysts Estimate Meridian Bioscience (VIVO) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-19-19 10:43AM	A Look At The Intrinsic Value Of Meridian Bioscience, Inc. (NASDAQ:VIVO) Simply Wall St.
Apr-18-19 08:48AM	Meridian Launches a New Inhibitor Tolerant qPCR Reagent to Significantly Simplify Molecular Diagnostic Workflows From Crude Samples GlobeNewswire
Apr-10-19 04:55PM	Meridian Bioscience to Hold Second Quarter 2019 Financial Results Conference Call on April 30, 2019 GlobeNewswire
Apr-02-19 06:59AM	Meridian Bioscience Announces Preliminary Second Quarter 2019 Revenue Results; Updates Fiscal 2019 Guidance GlobeNewswire -19.32%
Mar-27-19 12:03PM	Why Meridian Bioscience, Inc.s (NASDAQ:VIVO) Cash Is A Factor You Need To Consider Simply Wall St.
Mar-15-19 10:03AM	Here's Why You Should Buy Masimo (MASI) Stock Right Now Zacks
08:31AM	BD's Venovo Gets FDA Nod, Interventional Arm to Get a Boost Zacks
Mar-14-19 08:38AM	Here's Why You Should Invest in Stryker (SYK) Stock Right Now Zacks
Mar-05-19 08:26AM	Did Meridian Bioscience, Inc. (NASDAQ:VIVO) Insiders Sell Shares? Simply Wall St.
Feb-07-19 07:30AM	Meridian Launches New Range of Lyo-Ready PCR Mixes GlobeNewswire
Feb-04-19 08:20AM	Market Trends Toward New Normal in Welltower, Ferrari N.V, Caesars Entertainment, Cohu, Mountain Province Diamonds, and Meridian Bioscience Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Feb-01-19 06:44PM	Edited Transcript of VIVO earnings conference call or presentation 24-Jan-19 2:00pm GMT Thomson Reuters StreetEvents
Jan-29-19 04:10PM	Medical Products Industry Outlook: Plenty of Upside Left Zacks
Jan-25-19 09:38PM	Meridian Bioscience (VIVO) Q1 2019 Earnings Conference Call Transcript Motley Fool
Jan-24-19 08:45AM	Meridian Bioscience (VIVO) Tops Q1 Earnings Estimates Zacks
07:41AM	Meridian Bioscience: Fiscal 1Q Earnings Snapshot Associated Press
07:30AM	Meridian Bioscience Reports First Quarter 2019 Operating Results, Declares Regular First Quarter Cash Dividend, and Provides Updated Fiscal 2019 Guidance GlobeNewswire
Jan-23-19 10:14AM	A Spotlight On Meridian Bioscience, Inc.s (NASDAQ:VIVO) Fundamentals Simply Wall St.

Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms and technologies, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; rapid fluorescence-based immunoassay platform under the Curian brand; rapid single-use immunoassays under the ImmunoCard and ImmunoCard STAT! brand names; enzyme-linked immunoassays under the PREMIER brand; and anodic stripping voltammetry, an electrical chemical sensor platform for quantitative determination under the LeadCare and PediaStat brands. This segment's products are primarily used in the detection of infectious diseases caused by various bacteria, viruses, parasites, and pathogens. Its products consists of gastrointestinal assays, including tests for C. difficile, Enterohemorrhagic E. coli, Campylobacter jejuni, H. pylori, Cryptosporidium, giardia lamblia, and calprotectin; respiratory illness assays, such as tests for Group A Streptococcus, Influenza, M. pneumoniae, Bordetella pertussis, and respiratory syncytial virus; blood chemistry assays; and tests for Group B Streptococcus, Chlamydia trachomatis, Neisseria gonorrhea, Herpes Simplex Virus Type 1 and Type 2, and Malaria. This segment sells its products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by researchers, agri-bio companies, and IVD manufacturing companies. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Baldasare Bryan T	Exec VP & CFO	Jun 30	Option Exercise	19.71	1,500	29,565	54,137	Jul 02 01:52 PM
Williams Felicia	Director	Mar 16	Buy	6.02	1,550	9,331	5,717	Mar 17 01:55 PM
Kenny John P.	Chief Executive Officer	Mar 12	Buy	5.78	30,000	173,541	238,324	Mar 13 09:05 AM
Baldasare Bryan T	Exec VP & CFO	Mar 10	Buy	6.97	2,000	13,936	52,637	Mar 11 01:47 PM
McIlwraith John	Director	Feb 25	Buy	7.59	5,000	37,950	17,167	Feb 26 09:01 AM
Rice John McCune Jr.	Director	Feb 24	Buy	7.52	3,000	22,547	12,167	Feb 26 08:51 AM
Kenny John P.	Chief Executive Officer	Feb 21	Buy	7.65	10,000	76,546	208,324	Feb 24 11:01 AM
PHILLIPS DAVID	Director	Nov 12	Buy	8.06	10,000	80,626	48,616	Nov 13 10:49 AM
Kenny John P.	Chief Executive Officer	Nov 08	Buy	7.73	20,000	154,588	198,324	Nov 12 08:08 AM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience